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Cardiac baroreceptor sensitivity: A prognostic marker in pre-
dialysis chronic kidney disease patients?
Background. Small, uncontrolled studies of dialysis-
dependent chronic kidney disease (CKD) patients have demon-
strated abnormalities of cardiovascular autonomic control and
vascular compliance, which may contribute to adverse cardio-
vascular morbidity in this population. However, there is little
information utilizing newer, noninvasive techniques in predial-
ysis patients with increasing degrees of uremia.
Methods. One hundred and five nondialysis CKD patients
with a median GFR of 23 mL/min/1.73m2 (range: 6 to 102) at
baseline were studied. Cardiac baroreceptor sensitivity (BRS)
was recorded by time- and frequency-domain techniques, and its
relationship with increasing degrees of uremia studied. During
a mean follow-up period of 42 months (range: 3 to 70), primary
(death, dialysis, transplantation) and secondary (fatal and non-
fatal cardiovascular events) outcome measures were recorded.
The importance of cardiac BRS in comparison to other impor-
tant renal and cardiovascular prognostic variables in predicting
outcome was assessed.
Results. Median cardiac BRS by time domain analysis at base-
line was 8.85 msec/mm Hg (interquartile range: 6.85), and im-
paired cardiac BRS was related to reduced GFR, increasing age,
and hypertension on quantile regression analysis. ‘Impaired’
cardiac BRS was associated with a trend toward increased like-
lihood of both primary and secondary outcomes, and may act as
a surrogate measure of other cardiovascular risk factors, includ-
ing age, hyperlipidemia, hypertension, previous cardiovascular
disease, and doubling of creatinine.
Conclusion. Nondialysis-dependent CKD patients have im-
paired cardiac BRS, and this was related to decreasing GFR.
There was a trend toward poorer prognosis in patients with im-
paired cardiac BRS that requires further study. Cardiac BRS
may provide a simple, bedside, noninvasive assessment of over-
all cardiovascular risk in this population.
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Recent studies suggest that autonomic nervous sys-
tem dysfunction (AD) is associated with an increased
risk of mortality in various disease states, including my-
ocardial infarction [1, 2], diabetes [3–5], acute stroke [6],
and hypertension or prevalent cardiovascular disease [5].
The Autonomic Tone and Reflexes After Myocardial In-
farction (ATRAMI) study, for example, assessed cardiac
baroreceptor sensitivity (BRS) within 28 days of an acute
myocardial infarct and demonstrated that low cardiac
BRS (<3.0 ms/mm Hg) carried a significant risk of cardiac
mortality over a mean follow-up period of 21 months [2].
This effect was independent of left ventricular dysfunc-
tion and of ventricular arrhythmias.
In a chronic kidney disease (CKD) population, several
studies have demonstrated a higher incidence of cardiac
morbidity and mortality in patients with autonomic
dysfunction [7–9]. In terms of morbidity, Jassal et al
[7] showed an increased incidence of arrhythmias on
24-hour electrocardiograph (ECG) monitoring in
hemodialysis patients who had autonomic dysfunction
on standard tests. Krivoshiev et al [8] compared the
corrected QT interval (QTc) on ECG with the Valsalva
test and deep breathing test in 20 hemodialysis patients,
and reported a marked negative correlation between
the duration of the electrical systole of the heart and
the results of the two tests of autonomic function: R =
−0.7058, P < 0.001 between QTc and change of heart rate
in deep breathing, and R = −0.7133, P < 0.001 between
QTc and the Valsalva ratio. Citing their experience of
seven hemodialysis patients with significantly prolonged
QTc intervals who had died of sudden cardiac death,
they concluded that uremic neuropathy could predispose
to sudden cardiac death by impairing the function of
the parasympathetic nervous system. Finally, Tozawa et
al prospectively studied 144 hemodialysis patients, and
reported a hazard ratio for all-cause mortality that was
increased 1.63 times per 1% increase in coefficient of
variation in systolic blood pressure (SBP) [9].
However, these studies were based exclusively on dial-
ysis patients, when changes in cardiovascular autonomic
control and its consequences may be less amenable to
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therapeutic modification. Therefore, it is interesting that
Agarwal et al have reported impaired BRS and parasym-
pathetic nervous system dysfunction in 25 CKD patients
using invasive methodologies, though this was shortly be-
fore their patients became dialysis dependent [10]. Fur-
thermore, Hathaway et al utilized noninvasive frequency
domain measures of 24-hour heart rate variability, and
reported impaired values in CKD patients compared
to controls. Though this study included 43 nondialysis-
dependent patients, they nonetheless had advanced renal
impairment and were awaiting renal transplantation [11].
To our knowledge, there is little information on cardio-
vascular autonomic control, as assessed by noninvasive
cardiac BRS techniques, in a predialysis CKD population.
In particular, the effects of renal impairment on cardiac
BRS independent of other cardiovascular variables have
not been studied. Furthermore, the association between
cardiovascular AD in predialysis patients and prognosis
is unclear.
METHODS
Subjects
One hundred and nine predialysis CKD patients were
recruited from the outpatient clinics of the University
Hospitals of Leicester Nephrology Department between
May 1998 and April 2003. For the purposes of study anal-
ysis, the study was closed to follow-up of primary and
secondary outcome events on March 31, 2004 (census
date). The mean duration of follow-up was 42 months
(range 3 to 70 months). The following patient groups
were excluded from the study: congestive cardiac failure,
atrial fibrillation, or unstable vascular disease (defined by
any episode of acute coronary syndrome, stroke, or tran-
sient ischemic attack in the preceding 6 months); diabetes
mellitus, amyloidosis, or any other conditions associated
with autonomic neuropathy. Most patients were taking
medication, including antihypertensive and statin ther-
apy, with potential cardiovascular and autonomic effects
(Table 1). It was not considered ethical to discontinue
these medications during baseline assessment of cardiac
BRS, and these medications were continued throughout
the study period, although the presence or absence of car-
diovascular medication was included as a variable in the
subsequent statistical analysis.
All subjects gave their informed consent, and the
Leicestershire Local Research Ethics Committee ap-
proved the study.
Protocol
Height, weight, and body mass index were recorded
at the first visit. A baseline glomerular filtration rate was
measured by a plasma iodohexol clearance technique [12]
in the majority of patients, though this was not possible
in 11 patients in whom 24-hour urinary creatinine clear-
Table 1. Baseline characteristics of study population
Parameter N (%)
Ethnicity
Caucasian 95 (91)
South Asian 10 (9)
Smoking status: current/ex-smoker 51 (49.5)
Comorbid conditions
Hypertension 85 (81)
Ischemic heart disease 14 (13)
Other vascular disease 11 (11)
Hyperlipidemia 32 (31)
Causes of chronic kidney disease
Autosomal polycystic kidney disease 29 (28)
Chronic pyelonephritis/interstitial nephritis 11 (11)
Glomerulonephritis 30 (29)
Hypertension 8 (8)
Renovascular disease 5 (5)
Vasculitis 3 (3)
Other 11 (11)
Unknown 18 (17)
Baseline therapy (at cardiac BRS estimation)
ACE inhibitor/angiotensin II antagonist 57 (54)
Alpha-blocker 20 (19)
Beta-blocker 32 (31)
Calcium channel antagonist 45 (43)
Diuretic 49 (47)
Aspirin 14 (13)
Statin 26 (25)
ance was used as a surrogate marker. Routine investi-
gation of hemoglobin, creatinine, and total cholesterol
was assessed in the week prior to cardiac BRS measure-
ment. In addition, another serum creatinine estimation
was recorded at census date, or within six months before
census date.
On the day of cardiac BRS measurement, all patients
attended the cardiovascular laboratory at least 2 hours
after a light meal, and having abstained from smoking,
alcohol, and caffeinated products for at least 12 hours.
Investigations were carried out in a quiet room with an
ambient temperature of 20 to 24◦C, and patients were
asked to micturate prior to the study. After it was deter-
mined that there was no interarm difference in BP greater
than 10 mm Hg, casual supine BP was measured on three
occasions with a standard mercury sphygmomanometer
and cuff of appropriate size, and the mean value was used
in subsequent analysis. Subjects were fitted with chest
leads for continuous ECG recording (model CR7, Car-
diac Recorders Limited, London, UK) and the appro-
priately sized cuff of the 2300 Finapres noninvasive BP
monitor (Ohmeda, Englewood, CO, USA). This is a fully
automated device that allows continuous noninvasive as-
sessment of finger arterial pressure. It utilizes the arte-
rial clamp technique of Penaz [13] and is well validated
against intra-arterial BP measurement in all age groups
[14, 15]. The cuff was fitted to the middle finger or thumb
of the nondominant arm and maintained at heart level by
resting on an adjustable support throughout.
After a resting period of at least 15 minutes, and af-
ter achievement of a satisfactory BP signal from the
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monitor and the stabilization of BP at the same level
(mean 2-minute BP levels not varying by >10 mm Hg
over ≥10 min), recordings were performed for three se-
quential periods of 10 minutes each. The Finapres has a
built-in system (Physio-Cal) that briefly interrupts the BP
recording automatically to keep the finger arteries fully
unloaded and the transmural pressure equal to zero (usu-
ally for 2 to 3 beats every 70 beats). This was switched off
during the recording period but applied at 10-minute in-
tervals during the monitoring period. Subjects were asked
to maintain a respiratory rate >15 breaths per minute,
although respiratory rate and tidal volume were not for-
mally measured. The analog outputs from the Finapres
and simultaneous surface ECG recordings underwent
analog-to-digital conversion at a rate of 200 samples per
second, and were downloaded to a dedicated personal
computer for subsequent analysis and noninvasive esti-
mation of cardiac BRS.
Patients subsequently continued with their usual
follow-up at the nephrology outpatient clinics. Following
the close of the study, end points were recorded retro-
spectively from a number of sources, including hospital
medical records, the nephrology department information
system (PROTON), and the registrar for births, mar-
riages, and deaths in Leicestershire and Northampton-
shire. Causes of death were ascertained from either the
coroners’ reports or death certificates, completed inde-
pendently of the study investigators by the patients’ at-
tending physician.
Data analysis
Software specially written by the Leicester Warwick
Medical School Division of Medical Physics, and which
is in routine use in the department in which these stud-
ies were undertaken [16], was used in the offline analysis
of the beat-to-beat BP and pulse interval (PI) record-
ings. The derived PI and SBP were analyzed by means of
power spectral analysis (PSA) with fast Fourier transform
(FFT) with 512 samples. The data segments used were
extracted under visual inspection from the most stable
(i.e., stationary) segment of each 10-minute recording.
The beat-to-beat series of PI and SBP were interpolated
with a third-order polynomial and resampled with an in-
terval of 0.5 seconds to produce signals with a uniform
time axis. The power spectra were obtained as the average
of three recordings for each patient, and were smoothed
with a 13-point triangular window. Estimates of power
spectra of PI and SBP, coherence function, and frequency
response between PI and SBP with 58 degrees of freedom
(df) were thus produced. Coherence between BP and PI
variability reflects the amount of linear coupling between
the two spectra and is, therefore, comparable to the cor-
relation coefficient in regression analysis. A coherence
value >0.40 was considered significant [17]. Recordings
with an ectopy rate >2% were rejected. (Spikes on the
resampled tracings of the PI and SBP recordings were
manually removed, and a straight line was interpolated
by the computer, although resampled tracings with >4
spikes were excluded from subsequent analysis to avoid
bias.) PSA was undertaken to calculate the cardiac BRS
as the combined and LF a-index. Cardiac BRS estimation
was also made utilizing time-domain analysis techniques,
with combined pressor and depressor sequences.
Outcome measures
The primary outcome measure included death and
end-stage renal disease, defined by the need for long-
term dialysis or renal transplantation. The secondary out-
come of fatal and nonfatal cardiovascular events was also
recorded, and included a composite of myocardial in-
farction, new-onset arrhythmias associated with hemo-
dynamic compromise, stroke, hospitalization for angina
or heart failure, coronary or other revascularization, and
death from cardiovascular causes.
Statistical analysis
Values for the clinical and nonclinical continuous pa-
rameters were expressed as mean ± standard deviation.
The distribution patterns of all the parameters were ex-
plored using the box plot and normal Q-Q plot. We have
used the quantile regression technique (QR), while ex-
ploring the association of cardiac BRS with the vari-
ous clinical parameters. The generalized linear regression
(GLS) and even regression models with nonlinear trans-
formations did not provide good fit, the problems of non-
normality of regression residuals and heteroscedasticity
being evident in the course of model fitting. The QR is a
nonparametric statistical technique based on conditional
quantile functions, whereas the classic linear regression
methods based on minimizing sums of squared residu-
als enables us to estimate models for conditional mean
functions [18, 19]. Five quantiles were used to obtain
the best-fitted regression model, and the computations
were carried out using SPLUS 6.1 (Insightful Corpora-
tion, USA) and SHAZAM (SHAZAM Project, Univer-
sity of British Columbia, Vancouver, Canada) computa-
tion software.
To explore the influence of various risk factors on
outcomes, the multiple logistic regression technique was
used, and the influential risk factors in the models were
introduced following ‘step-wise’ technique. The Cox re-
gression technique with ‘step-wise’ selection of risk fac-
tors was employed to assess the survival patterns for both
primary and secondary outcomes, and the inclusion of
various risk factors in the regression models was based
on the likelihood ratio criteria. The Kaplan-Meier es-
timates were obtained for primary and secondary out-
comes, with factors differentiating between ‘normal’ and
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Table 2. Baseline clinical and laboratory parameters of study
population
Parameter Mean (SD)
Hemoglobin g/dL 13.19 (1.91)
Serum creatinine lmol/L 282.75 (173.48)
Total cholesterol mmol/L 5.64 (1.05)
Clinic systolic blood pressure mm Hg 134 (14)
Clinic diastolic blood pressure mm Hg 80 (8)
Body mass index kg/m2 27.66 (4.37)
Stage of chronic kidney disease [20]a
Stage 1: GFR >90 mL/min/1.73m2 1 (1)
Stage 2: GFR 60 to 89 12 (11)
Stage 3: GFR 30 to 59 27 (26)
Stage 4: GFR 15 to 29 39 (37)
Stage 5: GFR <15 24 (23)
Cardiac BRS by CKD stage msec/mm Hg
Stage 1 11.27 (1 patient only)
Stage 2 11.25 (6.67)
Stage 3 12.96 (6.67)
Stage 4 10.63 (7.83)
Stage 5 8.22 (5.80)
Cardiac baroreceptor sensitivity calculated by combined a-index. All data are
presented as mean (standard deviation), except anumber (%).
‘impaired’ levels of cardiac BRS (as assessed by com-
bined pressor and depressor sequences). Cardiac BRS
was dichotomized at the median value for the study pop-
ulation as described previously [2, 6]: ‘normal’ ≥median,
‘impaired’ <median. The survival plots were based on the
Kaplan-Meier analysis, and the log rank test was used to
test for differences between survival curves. In all statisti-
cal procedures, a P value of less than 0.05 was considered
to indicate statistical significance.
RESULTS
One hundred and nine patients were recruited to this
study between May 1998 and April 2003 from the out-
patient clinics of the University Hospitals of Leicester
NHS Trust Nephrology Department, although four pa-
tients were subsequently excluded following data analysis
due to interference from ectopic beats in the derivation of
BRS indices. In total, 105 patients (74 male) of median age
57 years (range: 24–80) were included in the study, and
relevant demographic information is presented in Table 1.
Most patients had a history of hypertension (81%), and
were taking vasoactive medication during the study pe-
riod (Table 1). While predialysis CKD patients were re-
cruited with a range of renal impairment, the distribution
of GFR was highly positively skewed (coefficient of skew-
ness: 1.82), with 65 patients having a GFR <30 mL/min
(Table 2). Details of other baseline clinical parameters,
including creatinine, hemoglobin, total cholesterol, and
casual SBP and DBP, are presented in Table 2.
Baseline levels of median (IQR) cardiac BRS were 8.85
(6.85), 7.67 (7.05), and 8.78 (7.38) msec/mm Hg, calcu-
lated by combined pressor and depressor sequences, LF
a-index, and combined a-index, respectively. The exis-
tence of outliers and skewed patterns in the distribution
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Fig. 1. Box plots of the cardiac baroreceptor sensitivity measurements
and glomerular filtration rate. All techniques: ABRS, combined a-index
BRS; LFBRS, low frequency BRS; CTBRS, combined time-domain
BRS (msec/mm Hg) and GFR (mL/min/1.73 m2).
of BRS measurements and GFR by all techniques can
be observed in Figure 1. The relation of BRS with other
common risk factors, including age and BP, is known to
be nonlinear. The relationship between BRS and im-
paired renal function, as measured by GFR, was as-
sessed by both parametric and nonparametric regression
techniques. The Spearman’s rank correlation coefficients
between GFR and cardiac BRS were significant for the
combined pressor and depressor (0.30) and combined a-
index (0.27) measurements only, at the 1% level. In ad-
dition, the patterns of relationships between GFR and
all BRS measurements were explored using the nonpara-
metric kernel smoothing technique. It can be seen that the
relationships were of a similar pattern (Fig. 2). Regression
fits for all measurements of cardiac BRS (with stepwise
selection of all possible factors) suggested the presence
of heteroscedasticity and non-normality in error distri-
bution. Quantile regression techniques with logarithmic
transformation of cardiac BRS gave the best possible fits,
among various linear and nonlinear (Box-Cox transfor-
mation) alternatives. The regression estimates are pre-
sented in Table 3. Logarithmically transformed cardiac
BRS was significantly associated with GFR for combined
pressor and depressor and LF a-index measures, but not
with the combined a-index technique (Table 3). Clinic
SBP, age, and BMI were significantly negatively associ-
ated with all measures of cardiac BRS (Table 3), the se-
lection of covariates in these regression analyses being
based on the statistical model fit criteria [18]. In addition,
the patterns of the residuals from the regression fits were
explored, and the estimates of the variances and the coef-
ficients of skewness (SK) of the regression residuals are
presented in Table 3. All three models fitted well with very
small coefficients of skewness for the regression residuals
and low standard errors (SE).
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Fig. 2. Plot of the relationship between glomerular filtration rate and
all measures of cardiac baroreceptor sensitivity using kernel smoothing
technique: (A) combined a-index (ABRS), (B) LF a-index (LFBRS),
(C) sequence BRS (CTBRS).
Over the mean study follow-up period of 42 months
(range, 3 to 70 months), there was an expected deterio-
ration in renal function with a mean creatinine at study
census date of 405 (SD: 297) lmol/L (GFR measurements
were not repeated). In total, 16 (15.2%) patients doubled
their creatinine during the follow-up period. Forty-six pri-
mary outcome events were recorded: 8 deaths (7.6%), 27
dialysis (25.7%), and 11 transplantations (10.5%). The
significance of various risk factors in predicting primary
outcome events was explored using multiple logistic re-
gression techniques; with a model including total choles-
terol [odds ratio (OR) = 7.43, 95% CI = 1.09 to 35.38,
P = 0.03), age (OR = 1.05, 95% CI = 0.95 to 2.95, P =
0.02), history of cardiovascular event (OR = 2.93, 95%
CI = 1.80 to 6.23, P = 0.01), and census creatinine (OR =
1.02, 95% CI = 1.07 to 1.20, P < 0.001), correctly predict-
ing 97.4% of combined primary outcome of death, dialy-
sis, and transplantation. A secondary outcome of fatal or
nonfatal cardiovascular event was recorded in 13 patients:
5 fatal (1 stroke, 1 acute myocardial infarction, 2 car-
diac failure secondary to ischemic heart disease, 1 sudden
death) and 13 nonfatal (3 stroke/TIA, 2 acute coronary
syndromes, 3 coronary revascularization, 1 renal angio-
plasty, 1 atheroembolic episode, 1 pulmonary embolism,
1 arryhythmia with hemodynamic compromise, and 1 is-
chemic bowel).
The analyses of the survival patterns for both primary
and secondary outcomes were performed separately by
stratifying the patients by ‘impaired’ (<median) and ‘nor-
mal’ (≥median) cardiac BRS [2, 6] using the combined
pressor and depressor sequence method. Results of the
Kaplan-Meier survival time analysis are presented in
Table 4. Though the survival times to either death, dial-
ysis, and transplantation (primary outcome) or fatal and
nonfatal cardiovascular event (secondary outcome) are
lower in the group of predialysis CKD patients with ‘im-
paired’ cardiac BRS, the survival distribution patterns
do not differ significantly between those with ‘impaired’
compared to ‘normal’ cardiac BRS (Table 4, Fig. 3). Of
note, median survival time to primary outcome is signifi-
cantly lower by 30.5 months in patients with doubling of
creatinine during the follow-up period (log-rank, P value
< 0.001, data not shown). Finally, the results obtained
from the Cox regression for both primary and secondary
outcomes are presented in Table 5. The final model and
the variable selection are based on the log likelihood
(Ln L) criteria. In particular, higher total cholesterol
and clinic SBP, history of previous cardiovascular event,
and presence of doubling of creatinine are significantly
associated with the risk of death, dialysis, or transplanta-
tion, while higher hemoglobin levels are associated with
a reduced risk (Table 5).
DISCUSSION
The present study has reported for the first time in
a predialysis CKD population that increasing impair-
ment of renal function as assessed by GFR is associ-
ated with impaired cardiovascular autonomic control as
assessed noninvasively by cardiac BRS measurements
using time- and frequency-domain techniques. Further-
more, when the study population was dichotomized into
groups with ‘impaired’ and ‘normal’ cardiac BRS, even
in this small study there was a trend toward poor prog-
nostic outcome in the ‘impaired’ cardiac BRS group, in
terms of progression to death, dialysis, and transplanta-
tion or the occurrence of fatal and nonfatal cardiovascular
events. However, recognized markers of poor cardiovas-
cular prognosis were more clearly associated with poor
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Table 3. Quantile regression results for cardiac baroreceptor sensitivity
Sequence BRSa Combined a-index LF a-index
Criterion Est. P value Est. P value Est. P value
Age −0.23 <0.001 −0.21 <0.001 −0.19 <0.001
Body mass index −0.34 <0.001 −0.28 <0.001 −0.11 <0.001
GFR 0.01 <0.001 0.003 0.10 0.03 <0.001
Clinic SBP −0.08 <0.001 −0.06 <0.001 −0.09 <0.001
Residual variance 0.81 0.99 0.95
SK (SE) 0.11 (0.54) −0.62 (0.53) −0.51 (0.48)
aCombined pressor and depressor sequences.
Table 4. Kaplan-Meier estimates for primary and secondary
outcomes in predialysis chronic kidney disease patients with ‘normal’
and ‘impaired’ cardiac baroreceptor sensitivity (assessed by combined
pressor and depressor sequence analysis)
Primary outcome Secondary outcome
‘Impaired’ ‘Normal’ ‘Impaired’ ‘Normal’
Total (number of
events)
52 (21) 53 (15) 52 (8) 53 (5)
Mean survival
time (SE)
52.0 (2.8) 57.7 (2.5) 61.6 (2.6) 63.7 (2.1)
95% confidence
intervals
46.4–57.5 52.8–62.6 56.5–66.7 59.7–67.8
Median survival
time (SE)
61.0 (10.1) 64.5 (3.8) 63.5 (17.4) 67.5 (3.8)
95% confidence
intervals
41.3–80.7 57.0–72.0 33.4–101.7 40.0–92.0
Log-rank P value 0.10 0.28
Primary outcome is death, dialysis, and transplantation, and secondary
outcome is fatal and nonfatal cardiovascular events. Survival time is expressed
in months.
outcome using Cox regression techniques, including age,
hypertension, hyperlipidemia, previous vascular disease,
and creatinine doubling, although cardiac BRS may act as
a simple, noninvasive, bedside assessment of a patient’s
overall cardiovascular risk, as in other populations [33].
Importantly, this simple test may identify ‘at risk’ pre-
dialysis CKD patients, where more aggressive risk factor
manipulation may improve cardiovascular prognosis.
Impaired cardiac BRS has previously been reported
in CKD patients, and has been one factor implicated
in intradialytic hypotension [10, 21–26]. However, these
studies have predominantly used invasive methods to as-
sess BRS in small populations of hemodialyzed patients.
In the only comparable study, Agarwal et al reported
a significantly reduced BRS of 3.88 msec/mm Hg in 25
nondialysis-dependent CKD patients compared to con-
trols [10]. However, the study was of young patients with a
mean age of 28.5 years. Also, this study estimated BRS us-
ing an invasive pressor method with phenylephrine, while
the present study assessed BRS from spontaneous fluc-
tuations in BP and PI measured noninvasively. A further
advantage of this technique are the powers of the vari-
ous components of the decomposed spectra of SBP and
PI variability can be compared, and this allows an as-
sessment of the integrity of the underlying sympathova-
gal balance of autonomic cardiovascular system control
[27, 28]. Converse et al have reported increased sympa-
thetic nerve discharge in hemodialysis-dependent CKD
patients, although formal studies of sympathetic activity
were not performed in the present study [34]. In keeping
with previous studies of hemodialysis-dependent CKD
patients [10, 21, 29–32], the present study reports im-
paired cardiac BRS in a predialysis CKD population. In-
deed, a similar result was found whether cardiac BRS was
assessed from the combined pressor and depressor se-
quences (time-domain) or from spontaneous fluctuations
in BP and PI (frequency-domain). A significant relation-
ship using frequency-domain techniques was only found
for cardiac BRS calculated from the a-index in the LF
band. However, this is more likely to indicate barorecep-
tor dysfunction because the combined a-index includes
the HF band, where there may be respiratory effects [28].
Such changes in cardiac BRS may be of prognostic
significance. Certainly, autonomic dysfunction has been
implicated in cardiovascular morbidity and mortality sec-
ondary to cardiac dysrhythmias following acute myocar-
dial infarction [2] and cerebrovascular disease [6]. The
present study reports a trend toward poor outcome in
predialysis CKD patients, whether for the primary out-
come of death, dialysis, and transplantation or the sec-
ondary outcome of fatal and nonfatal cardiovascular
events. However, these trends were not significant, and
indeed, other vascular and renal risk factors were signifi-
cant on Cox regression analysis, including age, hyperlipi-
demia, hypertension, a history of cardiovascular events,
and the presence of creatinine doubling. Interestingly,
other groups have reported similar findings in hyperten-
sive patients, and have suggested that the measurement
of cardiac BRS may act as a surrogate for the assessment
of multiple risk factors in a population at vascular risk
[33].
However, our small study has a number of important
limitations. First, it is clearly important to confirm these
findings in a larger population over a longer follow-up
period. Also, it would be important to determine that it
is possible to modify outcome by using such techniques
to identify a higher risk predialysis CKD population that
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Table 5. Cox regression results for primary and secondary outcomes
Primary outcome Secondary outcome
Est. b Exp. b Est. b Exp. b
Parameter (SE) P value (95% CI) (SE) P value (95% CI)
Age 0.16 0.003 1.18
(0.05) 1.06, 1.31
Cardiovascular event 0.75 0.001 2.11
(0.23) 1.34, 3.34
Clinic SBP 0.04 0.01 1.04
(0.01) 1.01, 1.07
Creatinine 0.003 0.008 1.003
(0.001) 1.00, 1.01
Double creatinine 0.55 0.006 1.74
(0.20) 1.17, 2.58
Hemoglobin −0.35 0.007 0.71
(0.1) 0.55, 0.91
Smoking history 2.09 0.02 8.09
(0.91) 1.36, 48.1
Total cholesterol 0.41 0.04 1.50
(0.19) 1.03, 2.20
Other vascular disease −2.27 0.01 0.10
(0.89) 0.12, 0.59
−2 Ln L 217.0 54.5
Primary outcome is death, dialysis, and transplantation, and secondary outcome is fatal and nonfatal cardiovascular events.
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Fig. 3. Kaplan-Meier survival plots for (A)
primary and (B) secondary outcomes, strat-
ified by ‘normal’ and ‘impaired’ cardiac
baroreceptor sensitivity (assessed by the com-
bined pressor and depressor sequence analy-
sis technique).
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is targeted with aggressive multifaceted risk factor mod-
ification therapies. Second, many patients were on car-
diovascular drugs with the potential to influence cardiac
BRS, including ACE inhibitors, beta- and alpha-blockers,
and statin therapy. However, for practical and ethical
reasons, it was not felt appropriate to discontinue ther-
apy for the purpose of conducting the study. Nonethe-
less, no statistically significant differences were found in
cardiac BRS between patients prescribed beta-blockers
and those not for all measures of cardiac BRS; sequence
BRS: 10.77 (9.32) versus 10.16 (6.68) msec/mm Hg, com-
bined a-index BRS: 11.72 (8.22) versus 10.37 (6.48), LF
a-index BRS: 9.78 (7.66) versus 9.08 (5.03), respectively.
Finally, the echocardiographic assessment of left ventric-
ular hypertrophy would have been a better assessment of
cardiovascular risk rather than the presence of hyperten-
sion, per se, although unfortunately, left ventricular mass
index was not calculated on all patients.
CONCLUSION
Cardiovascular disease is the leading cause of death
in CKD patients [35]. Previous studies have reported
abnormalities of reduced BRS to be associated with in-
creased mortality, particularly cardiovascular, in dialysis-
dependent CKD patients. Importantly, our preliminary
observations extend this relationship between impaired
renal function (GFR) and BRS to a predialysis CKD pop-
ulation, and indicate that impaired cardiac BRS may be
a simple marker of increased risk. However, it remains
to be demonstrated if therapeutic interventions to mod-
ify known cardiovascular risk factors could lead to an
improvement in cardiac BRS, and will improve cardio-
vascular outcomes in predialysis CKD patients.
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